Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

8d ago

ARVN

PremiumCompany Announcements

Arvinas Appoints New Chief Medical Officer for Clinical Programs

1M ago

ARVN

PremiumPress Releases

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

1M ago

ARVN

PremiumPress Releases

Arvinas to Participate in Upcoming Investor Conferences

2M ago

ARVN

PremiumPress Releases

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

2M ago

ARVN

PremiumPre-Earnings

ARVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

ARVN

More ARVN News >

ARVN News on the Web

2024-04-16

Analysts’ Top Healthcare Picks: Quanterix (QTRX), Intuitive Surgical (ISRG)

TipRanks News

Bullish

2024-04-12

Novartis Inks Deal for ARVN's Prostate Cancer Candidate

Yahoo Finance

Neutral

2024-04-12

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Zacks

Neutral

2024-04-11

Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential

TipRanks News

Bullish

2024-04-11

UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion

Yahoo Finance

Neutral

2024-04-11

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Yahoo Finance

Neutral

2024-04-09

Is Arvinas Stock a Solid Choice Right Now?

Yahoo Finance

Neutral

2024-04-09

Is Arvinas (ARVN) Stock a Solid Choice Right Now?

Zacks

Neutral

News Score - Last 7 Days

Neutral

ARVN

Sector Average

Media Buzz

This Week3 articles

Weekly Average2.5 articles

News Sentiment

This Week100%

Sector Average63%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARVN’s Media Buzz Sentiment?

3 articles about ARVN were published this week. In an average week, 2.5 articles are published.

What is ARVN’s weekly average amount of articles?

In an average week, 2.5 articles about ARVN are published.

What is ARVN’s News Sentiment?

100% of articles about ARVN were positive this week, compared to its sector average of 63%.

Healthcare Stocks that are Trending in the News

ELVElevance Health

CGEMCullinan Management

EWEdwards Lifesciences

MRNSMarinus

INSPInspire Medical Systems

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing